Oculis Holding AG Secures FDA SPA for Privosegtor Optic Neuritis Phase 3 Trial
ZUG, Switzerland – May 7, 2026 Oculis Holding AG announced that the U.S. Food and Drug Administration (FDA) has...
neuroprotection
Advertisement
InspireMD, Inc. Secures FDA IDE for CGUARDIANS III
MIAMI, May 1, 2026 InspireMD, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its...
LT3001 Stroke Drug Shows Phase 2 Functional Gains
Taipei, Taiwan — February 6, 2026 Lumosa Therapeutics has announced positive Phase 2 clinical trial outcomes for LT3001 (odatroltide),...
Government contract pursuit advances Halberd TBI nasal-spray program
JACKSON CENTER, Pa., November 3, 2025 — Halberd Corporation, in collaboration with Mississippi State University (MSU), announced continued efforts...
Oculis Highlights Late-Stage Eye Pipeline at AAO 2025
October 14, 2025 | Zug, Switzerland — Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company advancing therapies for...
Advertisement
